Specifically, COX-2 inhibition prevents the activation of antioxidant responses mediated by Nrf2 and Sp1, ultimately impairing the redox balance and sensitizing tumor cells to TMZ (Figure 7). This evidence concerns the gene PTGS2 and neoplasm.